Every 8-K that Oruka Therapeutics, Inc. (ORKA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ORKA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORKA filings page.
Oruka Therapeutics, Inc. (ORKA) appointed Todd Edwards as Chief Commercial Officer, effective August 24, 2026, under a July 22, 2026 letter agreement. Edwards is a veteran commercial leader from Arcutis Biotherapeutics, Incyte, UCB, AbbVie and TAP, with extensive experience in dermatology and immunology franchises.
His compensation includes a $525,000 annualized base salary, a discretionary annual bonus targeted at 40% of base salary, a stock option for 20,000 shares and 100,000 RSUs, plus a $200,000 signing bonus. If terminated without cause or he resigns for good reason, he is eligible for 12 months of salary and up to 12 months of company-paid health coverage, with enhanced cash and full equity acceleration upon qualifying terminations around a change in control.
Oruka Therapeutics, Inc. reported second quarter 2026 results and updated progress across its dermatology pipeline. The company is advancing ORKA-001, a half-life extended IL-23p19 monoclonal antibody, and ORKA-002, a half-life extended IL-17A/F monoclonal antibody, with multiple clinical data readouts planned through 2026 and into 2027. EVERLAST-A Week 28 data are expected at the end of the third quarter of 2026, with 52-week data for all participants anticipated in December 2026, while EVERLAST-B is fully enrolled ahead of schedule with Week 16 data expected in the fourth quarter of 2026. ORCA-SURGE Week 16 data are now expected in the first quarter of 2027, ORCA-SPLASH, a Phase 2 trial of ORKA-002 in hidradenitis suppurativa, has been initiated, and ORKA-004 is expected to enter the clinic in the fourth quarter of 2026.
As of June 30, 2026, Oruka held $1.1 billion in cash, cash equivalents, and marketable securities, which it expects will fund operations through an anticipated BLA filing for ORKA-001 and continued development of ORKA-002. Second quarter 2026 research and development expenses were $43.3 million versus $24.1 million a year earlier, and general and administrative expenses were $6.9 million versus $4.3 million. Other income, net, was $8.9 million, primarily from interest on higher cash and marketable securities. Net loss for the quarter was $41.2 million compared with $24.6 million in the prior-year quarter, reflecting increased investment in clinical programs and corporate infrastructure.
Oruka Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 2, 2026. Stockholders elected two Class II directors, Lawrence Klein and Chris Martin, to serve until the 2029 annual meeting. Klein received 43,918,579 shares voted for and 63,593 withheld, while Martin received 43,936,173 shares for and 45,999 withheld, with 1,267,194 broker non-votes.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026, with 45,206,297 shares for, 39,637 against, and 3,432 abstaining. In a non-binding advisory vote, stockholders approved the compensation of named executive officers, with 43,033,967 shares for, 875,114 against, 73,091 abstaining, and 1,267,194 broker non-votes.
Oruka Therapeutics, Inc. entered into a First Amendment to its IL-23 License Agreement with Paragon Therapeutics, Inc. This amendment broadens Oruka’s licensed field to cover all therapeutic, prophylactic, palliative and diagnostic uses of the IL‑23 program, including inflammatory bowel disease, subject to timing limits on when dosing may begin.
Under the amendment, Oruka may not dose a human patient in a clinical trial of ORKA‑001 for inflammatory bowel disease in a combination regimen until June 1, 2028, or as a monotherapy until June 1, 2030. If Oruka or a Paragon licensee completes a material transaction such as a change of control, any remaining restrictions outside the original field will continue only until June 1, 2028 and then terminate.
Oruka Therapeutics, Inc. reported preliminary first-quarter data and the closing of a common stock offering. The company estimates its cash, cash equivalents, and investments were approximately $496 million as of March 31, 2026, based on management’s internal data and subject to final accounting.
Oruka completed an underwritten public offering of 9,660,000 shares of common stock at $72.50 per share, made from its effective shelf registration statement. The underwriters also received a 30-day option to purchase up to an additional 1,449,000 shares at the same public offering price, less underwriting discounts and commissions. The company emphasizes that the preliminary cash figure is unaudited and should not be relied on as final results.
Oruka Therapeutics reported interim Phase 2a EVERLAST-A results for ORKA-001 in moderate-to-severe plaque psoriasis, showing 63.5% (40/63) of treated patients reached PASI 100, versus 4.8% (1/21) on placebo at Week 16.
Secondary measures were similarly strong, with 82.5% achieving PASI 90 and 84.1% reaching IGA 0/1. ORKA-001’s safety profile was comparable to placebo, with no serious treatment-emergent adverse events in the active arm and no injection site reactions. Phase 1 pharmacokinetic and pharmacodynamic data indicate drug levels and IL‑23 pathway inhibition remain above effective thresholds for a year after a single 600 mg dose, supporting potential once‑yearly dosing. The EVERLAST-A trial continues, with longer-term durability and safety data expected in the second half of 2026, while the dose-ranging Phase 2b EVERLAST-B study is enrolling, with results anticipated in 2027.
Oruka Therapeutics, Inc. reported that director Cameron Turtle resigned from its Board of Directors on December 11, 2025. The company stated that his resignation was not due to any disagreement over Oruka’s operations, policies, or practices.
On the same day, the board elected Christopher Martin as a Class II director, with a term ending at the 2026 annual meeting of stockholders, and named him Chair of the Compensation Committee and a member of the Audit Committee. As a non-employee director, he received a stock option for 35,000 shares of Oruka common stock vesting in 36 equal monthly installments and is eligible for annual cash retainers of $40,000 for board service, $12,000 for chairing the Compensation Committee, and $7,500 for Audit Committee service. The board determined he is independent under SEC and Nasdaq standards and reported no related-party transactions.
Oruka Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement of common stock and pre-funded warrants, raising an aggregate purchase price of approximately $180 million from institutional and accredited investors. Investors bought 10,933,405 shares of common stock at $15.00 per share and pre-funded warrants to purchase 1,066,666 shares at $14.999 per warrant, with a $0.001 per share exercise price.
The pre-funded warrants are exercisable at any time, subject to beneficial ownership limits initially set at 9.99%, adjustable up to 19.99% with 61 days’ notice. Following closing, Oruka reports 48,384,150 shares of common stock issued and outstanding and approximately 67.1 million shares issued and outstanding on a pro forma basis as of September 19, 2025, reflecting full conversion of Series B preferred stock and exercise of all pre-funded warrants.